Jiangsu Aland Health Products Co., Ltd. has launched a production line with an annual capacity of 5 billion nutrient gummies. Jiangsu Juyuan Medical Technology Co., Ltd., operational since October 2025, has already generated 38 million yuan in invoiced sales. The Puritan Sports Nutrition Powder project is accelerating its development... Transitioning from vitamin C production to a billion-yuan recombinant collagen cluster, Jingjiang in Taizhou, Jiangsu province, is rapidly establishing itself as a new focal point for the health industry in the Yangtze River Delta.
According to Taizhou's biopharmaceutical industry work plan, Jingjiang has formulated a development strategy for the biopharmaceutical chain based on a cluster model, centered around a "four parks, two bases" system. The city is fully committed to constructing a bio-manufacturing industrial park, machinery manufacturing park, synthetic biological API park, nutrition products park, along with a pilot research base and an animal health products base, aiming to create a unique biopharmaceutical industrial chain cluster in the Yangtze River Delta.
Accelerating the transition from laboratory to market, Jingjiang signed nine major health industry projects each valued over 100 million yuan in 2025, including two projects exceeding 500 million yuan. Jiangsu Jiesai Machinery Technology Co., Ltd.'s pharmaceutical centrifuge manufacturing project and Jiangsu Yahua Electronics Technology Co., Ltd.'s innovative medical cover glass project have both commenced operations in Jingjiang, with projected additional sales exceeding 500 million yuan upon full production.
On September 8, 2025, the Xinhong Bio-manufacturing Industrial Park project with a total investment of 10 billion yuan was signed and settled in Jingjiang. The project focuses on high-value-added precision nutrition products, cosmetic-device combinations, pharmaceutical intermediates, and the R&D and production of Class II and III medical devices, aiming to establish a bio-manufacturing base with advanced capabilities.
Leveraging Juyuan Biology as an anchor, the bio-manufacturing industrial park will serve as a platform, using order contracts as a driving force to attract leading cosmetics and collagen-based medical device enterprises. Among the key enterprises, Jiangsu Jianshan Juyuan Biotechnology Co., Ltd. stands out. As China's first high-tech enterprise using Pichia pastoris for recombinant collagen synthesis and Asia's largest medical-grade collagen production base, Juyuan Biology has achieved an annual production capacity of over 20 tons of pure collagen powder, successfully breaking the long-term monopoly of imported raw materials. In March 2025, the company showcased its leading technology and high-quality products at the 23rd World Aesthetic and Anti-Aging Conference, attracting global attention.
Synthetic biology is hailed as the "third biotechnology revolution." In the Jiangyin-Jingjiang Industrial Park, the construction of the synthetic biological API park is progressing vigorously. The park will develop into a full-chain industrial zone encompassing pilot platforms, incubation, and规模化 production, focusing on the R&D, pilot testing, and production of synthetic biological products such as vitamin C derivative series and zeaxanthin.
The first phase of the industrial park has secured land and entered the planning stage. It is expected to become an innovation hub in the synthetic biology field, facilitating the rapid transition of related products from laboratory to market.
Complementing the synthetic biological API park is the synthetic biology equipment and instrument manufacturing park. In recent years, Jingjiang's pharmaceutical supporting industry, with a focus on equipment manufacturing, has gradually formed a certain agglomeration effect. Saideli Pharmaceutical Machinery customizes 10-ton bioreactors for collagen enterprises, while Gongtang Chemical develops medical-grade stainless steel fermentation tanks. This ecosystem of local collaboration and coordinated innovation has reduced new product development cycles by 35% and costs by 20%.
Relying on key pharmaceutical equipment manufacturers like Saideli, Gongtang, and Yangyang, Jingjiang plans to develop high-throughput imaging flow cytometers and establish the nation's largest intelligent production base and research center for high-speed centrifuges, alongside the world's largest intelligent diagnostic center for centrifuges.
Recently, at the Ailand Global R&D Center within the Jingjiang Heng'ai Health Industrial Park, researchers were calibrating newly introduced 3D nutritional food printing equipment. As a leading enterprise in the global nutraceutical CDMO industry, Ailand operates across the Americas, Europe, and Asia, with five international R&D centers, a national CNAS laboratory, and four provincial-level R&D innovation platforms. It possesses over 10,000 mature nutraceutical formulas, 31 invention patents, 149 health food approvals, and nine products certified to United States Pharmacopeia standards.
Moving forward, leveraging the Heng'ai Health Industrial Park, the focus will be on creating a precision nutraceuticals and anti-aging health products park. Further development of product series including powders, granules, tablets, and gummies is planned, aiming to double the output value to 4 billion yuan, meet growing consumer health demands, and secure a significant position in the nutraceutical market.
Jiangsu Jiangshan Pharmaceutical Co., Ltd., starting from vitamin C production, operates the world's largest single VC production line. The company completed an equity change on March 11, 2024. The chairman stated the commitment to deepening and refining the VC market, while expanding the variety and scale of basic API R&D and production to consolidate its position as a global supply base and establish the largest vitamin API base in China.
Simultaneously, utilizing Yabo Animal Health Products Co., Ltd., Jingjiang is fully developing an animal health products production base. This involves further developing products like tablets, nutritional powders, nutritional biscuits, and capsules to create a top-tier global production and sales base for animal nutrition.
To promote industry-academia-research collaboration in biopharmaceuticals, Jingjiang is cooperating with the teams of Zhang Yan and Yang Chen from Shanghai Jiao Tong University's School of Life Sciences on "key technologies for synthetic probiotic communities and microbial function remodeling." Collaborations also include research on "the application of vitamin C and its series in the semiconductor industry" with Academician Liu Yunqi's team from the Chinese Academy of Sciences, and projects on "flavors, fragrances, and food additives" with the team of Zhang Xueli from the Tianjin Institute of Industrial Biotechnology, CAS, and leading industry enterprises. Currently, Jingjiang enterprises lead or participate in formulating seven national standards and three international standards in fields like collagen and functional foods.
Continuously enhancing its business environment, various stakeholders are协同 promoting the development of the health industry. Shortly after the Spring Festival in 2025, Jiangshan Pharmaceutical reapplied for its GMP Compliance Certificate and API Export Certificate for the EU. Under standard procedures, obtaining these certificates would require passing all inspections by the end of 2025. To help the company swiftly capture overseas market opportunities, the local market supervision authority proactively liaised multiple times with the provincial drug administration. Relevant inspections began on March 31, 2025, concluded on April 2, and the company received the certificates by mid-to-late April, saving nearly seven months.
Guided by the "Healthy China 2030" strategy, Jingjiang will focus on life health precision nutrition products, pharmaceutical equipment, and other fields. By leveraging key enterprises and specialized industrial parks, the city aims to accelerate industrial chain layout, make前瞻布局 in key technologies and core products for critical areas, and strive to achieve a health industry scale exceeding 10 billion yuan by 2030.